Romanelli G, Giustina A, Cimino A, Valentini U, Agabiti-Rosei E, Muiesan G, Giustina G
Cattedra di Patologia Speciale Medica, University of Brescia, Italy.
BMJ. 1989 Feb 4;298(6669):284-8. doi: 10.1136/bmj.298.6669.284.
To investigate whether captopril has any effect on microalbuminuria induced by exercise in normotensive diabetic patients with early stage nephropathy.
Randomised, double blind, crossover trial.
Outpatient department.
22 diabetics with stage II nephropathy (urinary albumin excretion rate less than 20 micrograms/min; 15 with type I diabetes and seven with type II), 32 patients with stage III nephropathy (urinary albumin excretion rate 20-200 micrograms/min; 14 with type I diabetes and 18 with type II), and 10 normal subjects.
Four exercise tests on a cycle ergometer: the first two under basal conditions and the third and fourth after subjects had received captopril (two 25 mg doses in 24 hours) or placebo (two tablets in 24 hours).
Exercised until 90% of maximum heart rate achieved.
Mean urinary excretion one hour after the first two exercise tests was 21 micrograms/min in normal subjects, 101 micrograms/min in diabetic patients with stage II nephropathy, and 333 micrograms/min in those with stage III nephropathy. Similar results were obtained after placebo. After captopril the urinary excretion rate one hour after exercise was significantly decreased in diabetics with stage II (36 micrograms/min) and stage III (107 micrograms/min) disease compared with placebo but not in normal subjects. Systolic and diastolic pressures were similar in the three groups after placebo and captopril had been given.
Captopril significantly reduces microalbuminuria induced by exercise in normotensive diabetics without affecting systemic blood pressure. Captopril may reduce renal intracapillary pressure.
探讨卡托普利对血压正常的早期肾病糖尿病患者运动诱发的微量白蛋白尿是否有影响。
随机、双盲、交叉试验。
门诊。
22例Ⅱ期肾病糖尿病患者(尿白蛋白排泄率小于20微克/分钟;15例Ⅰ型糖尿病患者和7例Ⅱ型糖尿病患者),32例Ⅲ期肾病患者(尿白蛋白排泄率20 - 200微克/分钟;14例Ⅰ型糖尿病患者和18例Ⅱ型糖尿病患者),以及10名正常受试者。
在自行车测力计上进行四项运动测试:前两项在基础条件下进行,第三项和第四项在受试者接受卡托普利(24小时内分两次服用25毫克剂量)或安慰剂(24小时内两片)后进行。
运动至达到最大心率的90%。
在前两项运动测试后1小时,正常受试者的平均尿排泄量为21微克/分钟,Ⅱ期肾病糖尿病患者为101微克/分钟,Ⅲ期肾病患者为333微克/分钟。服用安慰剂后得到类似结果。与安慰剂相比,服用卡托普利后,Ⅱ期(36微克/分钟)和Ⅲ期(107微克/分钟)肾病糖尿病患者运动后1小时的尿排泄率显著降低,但正常受试者无此现象。服用安慰剂和卡托普利后,三组的收缩压和舒张压相似。
卡托普利可显著降低血压正常的糖尿病患者运动诱发的微量白蛋白尿,且不影响全身血压。卡托普利可能降低肾内毛细血管压力。